Your browser doesn't support javascript.
loading
Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2.
Pattni, Karan; Hungerford, Daniel; Adams, Sarah; Buchan, Iain; Cheyne, Christopher P; García-Fiñana, Marta; Hall, Ian; Hughes, David M; Overton, Christopher E; Zhang, Xingna; Sharkey, Kieran J.
Afiliación
  • Pattni K; Department of Mathematical Sciences, University of Liverpool, Liverpool, UK.
  • Hungerford D; Centre for Global Vaccine Research, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.
  • Adams S; Graphnet Health, Milton Keynes, UK.
  • Buchan I; Institute of Population Health, University of Liverpool, Liverpool, UK.
  • Cheyne CP; Department of Health Data Science, University of Liverpool, Liverpool, UK.
  • García-Fiñana M; Department of Health Data Science, University of Liverpool, Liverpool, UK.
  • Hall I; Department of Mathematics and School of Health Sciences, University of Manchester, Manchester, UK.
  • Hughes DM; Joint Universities Pandemic and Epidemiological Research, Manchester, UK.
  • Overton CE; Department of Health Data Science, University of Liverpool, Liverpool, UK.
  • Zhang X; Department of Mathematics and School of Health Sciences, University of Manchester, Manchester, UK.
  • Sharkey KJ; Institute of Population Health, University of Liverpool, Liverpool, UK.
BMC Infect Dis ; 22(1): 270, 2022 Mar 20.
Article en En | MEDLINE | ID: mdl-35307024
BACKGROUND: From January to May 2021 the alpha variant (B.1.1.7) of SARS-CoV-2 was the most commonly detected variant in the UK. Following this, the Delta variant (B.1.617.2) then became the predominant variant. The UK COVID-19 vaccination programme started on 8th December 2020. Prior to the Delta variant, most vaccine effectiveness studies focused on the alpha variant. We therefore aimed to estimate the effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines in preventing symptomatic and asymptomatic infection with respect to the Delta variant in a UK setting. METHODS: We used anonymised public health record data linked to infection data (PCR) using the Combined Intelligence for Population Health Action resource. We then constructed an SIR epidemic model to explain SARS-CoV-2 infection data across the Cheshire and Merseyside region of the UK. Vaccines were assumed to be effective after 21 days for 1 dose and 14 days for 2 doses. RESULTS: We determined that the effectiveness of the Oxford-AstraZeneca vaccine in reducing susceptibility to infection is 39% (95% credible interval [34, 43]) and 64% (95% credible interval [61, 67]) for a single dose and a double dose respectively. For the Pfizer-BioNTech vaccine, the effectiveness is 20% (95% credible interval [10, 28]) and 84% (95% credible interval [82, 86]) for a single-dose and a double dose respectively. CONCLUSION: Vaccine effectiveness for reducing susceptibility to SARS-CoV-2 infection shows noticeable improvement after receiving two doses of either vaccine. Findings also suggest that a full course of the Pfizer-BioNTech provides the optimal protection against infection with the Delta variant. This reinforces the need to complete the full course programme to maximise individual protection and reduce transmission.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas Virales / COVID-19 Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: BMC Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas Virales / COVID-19 Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: BMC Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido